AbbVie competitorsClear all
Astellas Pharma's top competitors include Gilead Sciences, Immunomedics, Sanofi, Amgen, Bristol-Myers Squibb, Abbott, Merck Group, GSK, Novartis, Roche and Johnson & Johnson.
| Save Comparison |  Astellas Pharma Astellas Pharma is a pharmaceutical company focused on the development of drugs and medical solutions. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. |  Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. |  Sanofi Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products. |  Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with serious and life-threatening diseases. |  Abbott Abbott is a healthcare company specializing in diagnostics, medical devices, nutritionals, and branded generic medicines. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Roche Roche (also known as F. Hoffmann-La Roch) is a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics. |  Johnson & Johnson Johnson & Johnson is a global holding company that engages in the research and development, manufacture and sale of a range of products in the healthcare field. | ||
Founding Date | Founding Date 1923 | Founding Date 1987 | Founding Date 1982 | Founding Date 2004 | Founding Date 1980 | Founding Date 1887 | Founding Date 1888 | Founding Date 1668 | Founding Date 2000 | Founding Date 1996 | Founding Date 1896 | Founding Date 1886 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||||
Locations | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations Foster City, US HQ Abb, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Morris Plains, US HQ Rödermark, DE | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Kew, AU North Ryde, AU Wien, AT Machelen, BE see more | Locations New York, US HQ Braine L'alleud, BE Watermaal Bosvoorde, BE Montréal, CA Pudong Xinqu, CN Virum, DK Espoo, FI see more | Locations Lake Bluff, US HQ Tiranë, AL Buenos Aires, AR Yerevan, AM Doncaster, AU Macquarie Park, AU Melbourne, AU see more | Locations Darmstadt, DE HQ Hydra, DZ Csd, AR Bayswater, AU Bayswater, AU Macquarie Park, AU Wien, AT see more | Locations Brentford, GB HQ Boudouaou, DZ San Fernando, AR Abbotsford, AU Boronia, AU Ermington, AU Wien, AT see more | Locations New Brunswick, US HQ Buenos Aires, AR Chippendale, AU Wien, AT Minsk, BY Beerse, BE Brussel, BE see more | |||
Employees | Employees 15,8832% decrease | Employees 11,8007% increase | Employees 3666% increase | Employees 100,4094% decrease | Employees 23,4009% increase | Employees 30,00029% increase | Employees 107,0004% increase | Employees 58,1272% increase | Employees 99,4374% increase | Employees 105,7942% increase | Employees 97,735 | Employees 132,2002% decrease |
Valuation ($) | Valuation ($) 28.7 b | Valuation ($) 86.3 b | Valuation ($) 20.3 b | Valuation ($) 131.5 b | Valuation ($) 144.4 b | Valuation ($) 144.9 b | Valuation ($) 209.6 b | Valuation ($) 73.7 b | Valuation ($) 95.6 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 448.3 b |
Twitter followers | Twitter followers 50.4 k | Twitter followers 67.7 k | Twitter followers 605 | Twitter followers 141.2 k | Twitter followers 99.7 k | Twitter followers 152.2 k | Twitter followers 107 k | Twitter followers 20.7 k | Twitter followers 223.1 k | Twitter followers 292.8 k | Twitter followers 231.8 k | Twitter followers 231.9 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 25 | Number of tweets (last 30 days) 13 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 44 | Number of tweets (last 30 days) 102 | Number of tweets (last 30 days) 69 | Number of tweets (last 30 days) 282 | Number of tweets (last 30 days) 100 | Number of tweets (last 30 days) 79 | Number of tweets (last 30 days) 21 | Number of tweets (last 30 days) 51 | Number of tweets (last 30 days) 78 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 5.8 | Average likes per tweet (last 30 days) 81.2 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 15.3 | Average likes per tweet (last 30 days) 10.8 | Average likes per tweet (last 30 days) 6.8 | Average likes per tweet (last 30 days) 8.3 | Average likes per tweet (last 30 days) 4.7 | Average likes per tweet (last 30 days) 15.8 | Average likes per tweet (last 30 days) 11.5 | Average likes per tweet (last 30 days) 9.8 | Average likes per tweet (last 30 days) 10.6 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 96% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 98.04% | Percentage of tweets with engagement (last 30 days) 98.55% | Percentage of tweets with engagement (last 30 days) 59.93% | Percentage of tweets with engagement (last 30 days) 89% | Percentage of tweets with engagement (last 30 days) 93.67% | Percentage of tweets with engagement (last 30 days) 66.67% | Percentage of tweets with engagement (last 30 days) 80.39% | Percentage of tweets with engagement (last 30 days) 47.44% |
Alexa Website Rank | Alexa Website Rank 270550 | Alexa Website Rank 112610 | Alexa Website Rank 282560 | Alexa Website Rank 123373 | Alexa Website Rank 200877 | Alexa Website Rank 101235 | Alexa Website Rank 42367 | Alexa Website Rank 150790 | Alexa Website Rank 58088 | Alexa Website Rank 88970 | Alexa Website Rank 45834 | Alexa Website Rank 19571 |
Employee Rating | Employee Rating 3.1 | Employee Rating 3.8 | Employee Rating 3.2 | Employee Rating 3.3 | Employee Rating 4 | Employee Rating 4.1 | Employee Rating 3.9 | Employee Rating 4 | Employee Rating 3.8 | Employee Rating 4.2 | Employee Rating N/A | Employee Rating 4.2 |
Financial | ||||||||||||
Revenue (est.) | Revenue (est.) ¥1.3t (FY, 2020) | Revenue (est.) $24.7b (FY, 2020) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) (€926m) (FY, 2020) | Revenue (est.) $25.4b (FY, 2020) | Revenue (est.) $42.5b (FY, 2020) | Revenue (est.) $34.6b (FY, 2020) | Revenue (est.) €17.5b (FY, 2020) | Revenue (est.) £33.8b (FY, 2019) | Revenue (est.) $48.7b (FY, 2020) | Revenue (est.) CHF63.8b (FY, 2019) | Revenue (est.) $82.1b (FY, 2019) |
Cost of goods | Cost of goods ¥276.7b (FY, 2020) | Cost of goods $4.6b (FY, 2020) | Cost of goods N/A | Cost of goods €12.2b (FY, 2020) | Cost of goods $6.2b (FY, 2020) | Cost of goods $11.8b (FY, 2020) | Cost of goods $15b (FY, 2020) | Cost of goods €6.8b (FY, 2020) | Cost of goods £11.9b (FY, 2019) | Cost of goods $15.1b (FY, 2020) | Cost of goods CHF18.4b (FY, 2019) | Cost of goods $27.6b (FY, 2019) |
Gross profit | Gross profit ¥1t (FY, 2020) | Gross profit $20.1b (FY, 2020) | Gross profit $295k (FY, 2019) | Gross profit (€13.1b) (FY, 2020) | Gross profit $19.3b (FY, 2020) | Gross profit $30.7b (FY, 2020) | Gross profit $19.6b (FY, 2020) | Gross profit €10.7b (FY, 2020) | Gross profit £21.9b (FY, 2019) | Gross profit $33.5b (FY, 2020) | Gross profit CHF45.4b (FY, 2019) | Gross profit $54.5b (FY, 2019) |
Net income | Net income ¥195.4b (FY, 2020) | Net income $89m (FY, 2020) | Net income ($357.3m) (FY, 2019) | Net income €12.4b (FY, 2020) | Net income $7.3b (FY, 2020) | Net income ($9b) (FY, 2020) | Net income $4.5b (FY, 2020) | Net income €2b (FY, 2020) | Net income £5.3b (FY, 2019) | Net income $8.1b (FY, 2020) | Net income CHF14.1b (FY, 2019) | Net income $15.1b (FY, 2019) |
Operating ⚠ | ||||||||||||
Countries | Countries N/A | Countries 35 (FY, 2019) | Countries N/A | Countries N/A | Countries 100 (FY, 2019) | Countries N/A | Countries N/A | Countries 66 (FY, 2020) | Countries N/A | Countries N/A | Countries N/A | Countries 60 (FY, 2018) |
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 7 (FY, 2019) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 87 (FY, 2016) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 97 (FY, 2019) |
Manufacturing Sites | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites 92 (FY, 2019) | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites 23 (FY, 2019) | Manufacturing Sites N/A |
New Product Launches | New Product Launches N/A | New Product Launches N/A | New Product Launches N/A | New Product Launches N/A | New Product Launches N/A | New Product Launches N/A | New Product Launches 25 (FY, 2018) | New Product Launches N/A | New Product Launches 30 (FY, 2016) | New Product Launches N/A | New Product Launches N/A | New Product Launches N/A |
Patent Applications (US) | Patent Applications (US) N/A | Patent Applications (US) 394 (Dec, 2020) | Patent Applications (US) 275 (Sep, 2020) | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A | Patent Applications (US) N/A |
Patents (US) | Patents (US) N/A | Patents (US) 650 (Dec, 2020) | Patents (US) 390 (Sep, 2020) | Patents (US) N/A | Patents (US) 34 (FY, 2019) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products 22 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 12 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase I Trials Products (Immunology) | Phase I Trials Products (Immunology) 1 (Oct, 2020) | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) 5 (FY, 2019) | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) 7 (Dec, 2020) | Phase I Trials Products (Immunology) N/A |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) 1 (FY, 2020) | Phase I Trials Products (Oncology) 7 (FY, 2019) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 12 (FY, 2020) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 19 (FY, 2019) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 43 (Dec, 2020) | Phase I Trials Products (Oncology) N/A |
Phase I Trials Products (Other) | Phase I Trials Products (Other) 3 (Oct, 2020) | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) N/A | Phase I Trials Products (Other) 2 (Dec, 2020) | Phase I Trials Products (Other) N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2019) | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2019) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase II Trials Products (Immunology) | Phase II Trials Products (Immunology) 1 (Oct, 2020) | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) 4 (FY, 2019) | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) 9 (Dec, 2020) | Phase II Trials Products (Immunology) N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) 1 (FY, 2020) | Phase II Trials Products (Oncology) 2 (FY, 2019) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 6 (FY, 2020) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 14 (FY, 2019) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 7 (Dec, 2020) | Phase II Trials Products (Oncology) N/A |
Phase II Trials Products (Other) | Phase II Trials Products (Other) 2 (Oct, 2020) | Phase II Trials Products (Other) 1 (FY, 2018) | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) N/A | Phase II Trials Products (Other) 3 (Dec, 2020) | Phase II Trials Products (Other) N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 27 (FY, 2019) | Phase III Trials Products 4 (FY, 2019) | Phase III Trials Products N/A | Phase III Trials Products 14 (Feb, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 14 (FY, 2019) | Phase III Trials Products 44 (Q4, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Phase III Trials Products (Immunology) | Phase III Trials Products (Immunology) 1 (Oct, 2020) | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) 4 (FY, 2019) | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) 7 (Dec, 2020) | Phase III Trials Products (Immunology) N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) 4 (Oct, 2020) | Phase III Trials Products (Oncology) 1 (FY, 2019) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 9 (FY, 2019) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 22 (Q4, 2020) | Phase III Trials Products (Oncology) 26 (Dec, 2020) | Phase III Trials Products (Oncology) N/A |
Phase III Trials Products (Other) | Phase III Trials Products (Other) 1 (Oct, 2020) | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) N/A | Phase III Trials Products (Other) 1 (Dec, 2020) | Phase III Trials Products (Other) N/A |
Products | Products N/A | Products 24 (FY, 2019) | Products N/A | Products N/A | Products N/A | Products N/A | Products 1.5 k (FY, 2019) | Products 300 k (FY, 2020) | Products N/A | Products N/A | Products N/A | Products N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 91 (FY, 2019) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 44 (FY, 2016) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A |
Research and Development Centers | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers 12 (FY, 2019) | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers 29 (FY, 2019) | Research and Development Centers N/A |
Suppliers | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 68 k (FY, 2019) | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 3.5 k (Jun, 2018) |
US FDA Breakthrough Therapy Designations | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations N/A | US FDA Breakthrough Therapy Designations 6 (FY, 2017) | US FDA Breakthrough Therapy Designations 4 (FY, 2019) | US FDA Breakthrough Therapy Designations N/A |
Funding | ||||||||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 30m | Total funding raised $ 310m | Total funding raised $ 175.5m | Total funding raised $ 15.5m | Total funding raised $ 6.9m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised $ 2.8b | Total funding raised N/A |
For sources of this data, please see the company profile
View company profiles
Gilead Sciences
HQ
Foster City, US
Employees
11,800↑ 7% increase
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
View companyImmunomedics
HQ
Morris Plains, US
Employees
366↑ 6% increase
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companySanofi
HQ
Paris, FR
Employees
100,409↓ 4% decrease
Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
View companyAmgen
HQ
Thousand Oaks, US
Employees
23,400↑ 9% increase
Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products.
View company